SIRA return-to-work guidelines and medication

Expert integration of medication management and SIRA return-to-work guidelines in NSW workers compensation

Published 3 April 2026

Introduction

The State Insurance Regulatory Authority (SIRA) in New South Wales administers the workers compensation scheme under the Workers Compensation Act 1987 (NSW). A central focus of the scheme is facilitating safe and timely return to work for injured workers. Medication management is an integral component of return-to-work planning, as medications may either support or impede functional recovery and work capacity. For professional indemnity insurers and claims managers, understanding how to integrate medication governance with SIRA return-to-work principles is critical to optimal claims management.

This article provides a specialist overview of SIRA return-to-work guidelines and practical medication management strategies aligned with return-to-work objectives.

SIRA Return-to-Work Framework

SIRA's return-to-work framework emphasizes early intervention, graduated return to work, and collaboration between workers, employers, healthcare providers, and insurers. Key principles include:

• Early intervention: Return-to-work planning should commence early in the claim lifecycle, ideally within days of injury notification.
• Graduated approach: Return to work should be gradual, with incremental increases in hours and duties as the worker's functional capacity improves.
• Collaborative approach: Effective return-to-work planning involves coordination between all stakeholders including the worker, treating practitioners, employer, and insurer.
• Suitable duties: Work duties should be appropriate for the worker's current functional capacity and medical condition.
• Monitoring and adjustment: Return-to-work plans should be monitored and adjusted as the worker's capacity improves or if unforeseen barriers emerge.

SIRA provides guidance and resources for implementing effective return-to-work programs and has published detailed information on best practice approaches.

Medication and Functional Capacity Assessment

A critical component of return-to-work planning is accurate assessment of the worker's functional capacity. Medications significantly influence functional capacity through several mechanisms:

Functional capacity assessment should explicitly address medication-related functional limitations. Healthcare practitioners should document:

• Specific functional effects of each medication relevant to the worker's job role.
• Timing of side effects (immediate post-dose, cumulative over time).
• Dose-related effects and whether these might improve with dose adjustments.
• Potential for improvement as the worker adapts to the medication.

Pain Management and Return-to-Work Coordination

Pain management is frequently the central medication-related issue in workers compensation claims and directly impacts return-to-work feasibility. SIRA guidance emphasizes the importance of active pain management strategies including physical therapy, psychological support, and appropriately selected pharmacological therapy. Best practice includes:

• Integration of analgesic therapy with physical rehabilitation and exercise.
• Regular review of pain management efficacy and reassessment of analgesic therapy as the worker's condition evolves.
• Early transition from opioid to non-opioid analgesics where clinically appropriate.
• Deprescribing plans for short-term medications (opioids, benzodiazepines) with explicit target dates for cessation.
• Consideration of psychological factors in pain management and coordination with psychological interventions.

Pain management that relies primarily on opioid analgesics without concurrent physical rehabilitation or functional improvement may impede return to work. SIRA principles support multimodal pain management combining multiple therapeutic modalities.

Opioid Prescribing and Return-to-Work Barriers

Opioid-related functional impairment represents a significant barrier to return to work in some claims. Common opioid-related functional effects include sedation, cognitive impairment, motor incoordination, and psychological effects such as apathy or depression. For claims involving prolonged opioid therapy, insurers should:

• Assess whether opioid-related functional impairment is limiting return-to-work capacity.
• Document opioid dose and duration, recognizing that prolonged therapy increases dependence risk and functional impairment risk.
• Consider whether dose reduction or transition to non-opioid analgesics might improve work capacity.
• Engage treating practitioners on opioid management and return-to-work barriers.
• Consider independent medication review in complex opioid cases.

Benzodiazepines and Work Capacity

Benzodiazepine and related sedative prescribing presents a significant barrier to return to work. Benzodiazepines impair alertness, cognition, and motor function, creating safety risks in most work environments. SIRA principles do not support prolonged benzodiazepine therapy due to its impact on functional recovery. For claims involving benzodiazepine prescribing:

• Prescribing should be time-limited (2-4 weeks maximum) with explicit deprescribing plan.
• Return-to-work planning should account for benzodiazepine-related functional impairment.
• Early deprescribing support is appropriate and aligns with return-to-work objectives.
• Alternative interventions (psychological support, sleep hygiene, rehabilitation) should be prioritized.

Psychotropic Medications and Return-to-Work Considerations

Workers with mood disturbance, anxiety, or post-traumatic stress may require psychotropic medication in addition to psychological treatment. While selective serotonin reuptake inhibitors (SSRIs) are considered first-line treatment and generally have minimal functional impairment, some psychotropic medications may affect work capacity. Return-to-work planning should address:

• Specific functional effects of the prescribed psychotropic medication.
• Timing of treatment initiation relative to return-to-work planning.
• Coordination with psychological interventions and occupational rehabilitation.
• Regular review to assess whether psychological symptoms and medication effectiveness support return-to-work progression.

Work Capacity and Medication Review Coordination

Work capacity assessments should be coordinated with medication reviews to ensure comprehensive understanding of functional barriers. Where medication-related functional impairment is identified, consider:

Medication Adherence and Return-to-Work Success

Poor medication adherence may impede return-to-work success, particularly where medications are essential for pain control or psychological stability. Adherence barriers may include medication side effects, inconvenience of dosing schedules, or worker concerns about medication dependence. Support strategies include:

• Explicit discussion of medication adherence in return-to-work planning.
• Identification and management of adherence barriers.
• Engagement of pharmacists in medication counseling and adherence support.
• Regular monitoring of adherence and adjustment of medication strategies if adherence is problematic.

Independent Medication Review in Return-to-Work Planning

Independent medication reviews by specialist pharmacists provide valuable assessment of medication appropriateness and functional implications in complex claims. Medication review is particularly valuable in return-to-work planning where:

• Medication-related functional impairment is limiting return to work.
• Prolonged opioid, benzodiazepine, or other sedative prescribing is impeding functional recovery.
• Multiple medications are creating polypharmacy-related functional effects.
• Worker reports medication side effects affecting work capacity.
• Dispute exists regarding medication appropriateness or work capacity implications.

Return-to-Work Program Implementation with Medication Coordination

Effective return-to-work programs should explicitly integrate medication management. Key components include:

• Early assessment: Identify medication-related barriers early in the claim lifecycle.
• Medication optimization: Work with treating practitioners to optimize medication regimens and minimize functional impairment.
• Clear communication: Ensure medication-related functional information is clearly communicated to work capacity assessors, employers, and workers.
• Graduated progression: Coordinate medication management changes with graduated return-to-work progression.
• Monitoring: Regular review of return-to-work progress with attention to medication-related barriers and opportunities.

Barriers to Return-to-Work and Medication Management

Where return-to-work progress stalls, medication management should be reviewed as a potential barrier or opportunity. Questions to consider include:

• Is medication-related functional impairment limiting work capacity?
• Are there medication side effects that could be managed through dose adjustment or alternative medications?
• Is pain control adequate and appropriately integrated with rehabilitation?
• Are there psychological factors (anxiety, depression) requiring improved treatment?
• Is the medication regimen appropriate for the worker's current functional status?

Best Practice for Insurers

For SIRA insurers managing workers compensation claims, best practice medication governance integrated with return-to-work planning includes:

• Early coordination: Integrate medication assessment into return-to-work planning from early in the claim.
• Functional documentation: Ensure functional impact of medications is explicitly documented by treating practitioners.
• Regular review: Establish regular medication review protocols coordinated with return-to-work progression.
• Specialist engagement: Engage pain specialists, psychiatrists, or other specialists for complex medication scenarios affecting work capacity.
• Proactive deprescribing: Support time-limited deprescribing of opioids, benzodiazepines, and other medications as the worker's condition improves.